Driving CAGR as Kendle International SVP & CMO

brand building, sales effort and organizational leadership helped to deliver:

Five Year cagr from january 2004 - december 2008

• +44% CAGR BACKLOG
• +29% CAGR NET SERVICE revenue
• +71% cagr operating income
• +69% cagr net income

Source: kendle international 2008 annual report

Adding Brand and Asset Value as a Contract CMO

strategic LEADERSHIP and brand building HELPED clients to DELIVER:

"CBPE SECURES 22X INVESTMENT MULTIPLE ON SALE OF IDIS TO CLINIGEN GROUP PLC"

IDIS grew to become the clear global leader in the operation of Managed Access Programmes for pharmaceutical companies.  These programmes are designed to provide access to unlicensed medicines not available to patients via the traditional access route (many approved medicines may still may be unlicensed in certain countries), providing benefits not just for patients and healthcare professionals who have run out of treatment options, but also for the pharmaceutical and biotechnology companies that hold the products that could help.

Example creative work for the award winning "i did it with idis" campaign

CBPE News Release

"LDC completes exit of Synexus with 2.3x investment multiple"

​LDC has completed the exit of Synexus, a leading global research site group which provides patient recruitment and treatment services in support of drug research for clinical trials, in a deal that values the business at £178m. Synexus has been acquired by Jaguar Holding Company Luxembourg SARL and the transaction generates a 2.3x money multiple for LDC.

Headquartered in Manchester, UK, Synexus is one of the only global patient enrolment and investigator site management organisations (SMO). It enrols and manages patients for large, complex clinical trials on behalf of a number of leading international pharmaceutical, biotechnology and contract research organisations.

LDC News Release